Aciclovir

Aciclovir is an acyclic nucleoside analogue that mimics the natural building block guanosine; chemically it is a guanine base joined to a truncated, open side chain rather than the complete sugar ring found in ordinary nucleosides ^[1]. This unusual structure is central to its selectivity, because the molecule can be assembled into a chain-terminating form only where a viral enzyme is present to begin its activation ^[1]. It belongs to the broader family of antiherpetic nucleoside analogues and shares its mode of action with related agents such as penciclovir ^[3].

The compound emerged from research at Burroughs Wellcome, where investigators building on nucleoside chemistry, inspired in part by unusual sugars isolated from a Caribbean sea sponge, identified the acyclic guanosine derivative as a potent and unusually selective inhibitor of herpes simplex virus ^[1]. It was patented in the 1970s and reached medical use in the early 1980s. The underlying research contributed to the award of the 1988 Nobel Prize in Physiology or Medicine to Gertrude Elion and George Hitchings, recognizing the rational, target-directed style of drug design that the molecule exemplified ^[1].

Clinically, aciclovir is used to treat and suppress infections caused by herpes simplex virus types 1 and 2, such as cold sores, genital herpes, and herpes encephalitis, and by varicella zoster virus, the cause of chickenpox and shingles ^[3]. Prodrug strategies were later devised to improve its modest oral absorption; valaciclovir, the valine ester of aciclovir, is converted to the parent drug within the body and delivers far more of it into the circulation ^[2]. Antiviral agents of this class have also been examined as adjuncts in severe Epstein-Barr virus disease, though that evidence rests largely on case reports and remains uncertain ^[4].

Aciclovir is formulated for several routes, including oral tablets and suspensions, topical creams and eye ointments, and intravenous preparations for serious infections ^[3]. It is available generically under many trade names, the original being Zovirax, and is generally a prescription medicine in countries such as the United States and the United Kingdom ^[2]. Resistance can develop, most often in people with weakened immune systems, usually through mutations that disable the viral thymidine kinase, and such cases may call for alternative antivirals ^[3].

Oral and intravenous aciclovir are prescription; some topical forms are sold over the counter. It is usually well tolerated, with headache, nausea, and diarrhea the common oral complaints. The biggest cautions apply to the intravenous form and to people who are dehydrated or have kidney disease, because the drug can crystallize in the kidneys and injure them; good hydration and dose adjustment lower that risk. High levels, mostly in kidney impairment, can cause confusion, agitation, or tremor. Staying well hydrated and cutting the dose in renal impairment are the key precautions.

Aciclovir is filtered by the kidney as an organic anion substrate for OAT2 and OAT3 transporters; probenecid competitively inhibits this renal secretion and increases plasma levels ^[7]. This is a pharmacokinetic interaction; the clinical consequence is higher aciclovir exposure and potential accumulation, which can increase nephrotoxicity risk. The interaction is dose-dependent and clinically significant in renally impaired patients or those receiving high-dose intravenous aciclovir.

Aciclovir itself carries inherent nephrotoxicity risk independent of drug interactions, particularly in neonates and critically ill patients with underlying renal compromise ^[8]. Co-administration with other nephrotoxic agents such as NSAIDs, amphotericin B, or vancomycin increases the risk of acute kidney injury through additive tubular damage. This is a pharmacodynamic (toxic effects) rather than pharmacokinetic interaction, and the mechanism involves crystal-induced nephropathy. Electrolyte abnormalities and dehydration increase aciclovir nephrotoxicity; most drug-drug interactions with aciclovir remain poorly studied outside of the probenecid interaction and general renal risk factors.

Checking a whole stack? Run it through interactions + stacks.

Aciclovir was developed in the 1970s at Burroughs Wellcome by a team including Gertrude Elion and George Hitchings, pioneers of rational, mechanism-based drug design. It emerged from their systematic work on nucleoside analogues and proved to be a landmark antiviral because of the elegant way it is activated preferentially inside cells infected by a herpesvirus. Its selective mechanism, requiring a virus-encoded thymidine kinase to switch it on, contributed to the body of work that earned Elion and Hitchings a share of the 1988 Nobel Prize in Physiology or Medicine. Decades later, aciclovir remains a first-line antiviral against herpes simplex and varicella zoster viruses and is listed on the World Health Organization's List of Essential Medicines.

Aciclovir is one of the most trusted and thoroughly validated antivirals in medicine, widely regarded as a textbook example of selective drug design done right. Clinicians value it for its long safety record and its clever, self-targeting activation, which concentrates the active drug where the virus is actually replicating and largely spares healthy cells. Its reputation is strong enough that it remains a global essential medicine used for everything from cold sores and genital herpes to chickenpox and shingles. The honest limits are modest and well understood; oral absorption of the parent drug is limited, which is precisely why ester prodrugs such as valaciclovir were later designed, and rare resistance can arise in viruses that alter the activating enzyme.